Onkologie. 2012:6(5):282-283

Sunitinib in neuroendocrine tumors

Hana Šiffnerová
Onkologické oddělení Nemocnice České Budějovice, a.s.

Case history of 55 years old man with neuroendocrine tumor of liver, pankreas, mesentery, small intestine and mediastinum is decribed.

The treatment started with somatostatin analogs. The treatment with sunitinib was added due to progression of disease.

Keywords: neuroendocrine tumor, somatostatin analogs, sunitinib

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šiffnerová H. Sunitinib in neuroendocrine tumors. Onkologie. 2012;6(5):282-283.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yao JC, et al. One hundred years after, ,karcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072. Go to original source... Go to PubMed...
    2. Pavel M, et al. Everolimus plus octreotide long-acting repeatable for the treatment advanced neuroendocrine tumors with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012. Go to original source... Go to PubMed...
    3. Raymond E, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13. Go to original source... Go to PubMed...
    4. Kulke MH, et al. Activity of sunitinib in patiens with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.